Rocket Pharma (RCKT) Stock Forecast & Price Target

Rocket Pharmaceuticals is supported by a compelling Danon disease program in which the pivotal phase II success bar is now clearly defined at 7 of 12 patients meeting both responder criteria at 12 months, while early data show all six phase I evaluable patients responded and 3 of 4 initial phase II patients had substantial LVMI reductions of about 30% to 36%. The recalibrated Cohort 4 dose has shown encouraging safety in the first three patients, with no TMA or capillary leak observed, and durable follow-up is notable because five of six evaluable patients remained transplant-free with estimated transplant-free survival of 80% at approximately 58 months. Fundamentally, the outlook is strengthened by a large but underdiagnosed market of roughly 10,000 to 11,000 U.S. patients, more than 900 already identified, and financing that lifts cash runway into 3Q28 and potentially into 2029.

Rocket Pharmaceuticals is constrained by a weak financing profile, with runway only into 3Q28 and topline expected around mid-2028, leaving it funded to a readout but not through launch and likely dependent on further Hercules draws or equity. Its one approved product is not yet generating revenue, the majority of the pipeline remains clinical stage, and continuing cash burn means additional capital will probably be needed for R&D, regulatory work, and future sales and marketing, creating dilution and leverage risk. Fundamentally, the stock is also exposed to major execution uncertainty from the Danon clinical hold, possible FDA demands for longer pivotal trials, manufacturing complexity, and competitive and pricing pressure that could delay commercialization or compress returns.